References
- Meisner M. Update on procalcitonin measurements. Ann Lab Med 2014;34:263-73. https://doi.org/10.3343/alm.2014.34.4.263
- Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206-17. https://doi.org/10.1086/421997
- Delevaux I, Andre M, Colombier M, Albuisson E, Meylheuc F, Begue RJ, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 2003;62:337-40. https://doi.org/10.1136/ard.62.4.337
- Xu RY, Liu HW, Liu JL, Dong JH. Procalcitonin and C-reactive protein in urinary tract infection diagnosis. BMC Urol 2014;14:45. https://doi.org/10.1186/1471-2490-14-45
- Vouloumanou EK, Plessa E, Karageorgopoulos DE, Mantadakis E, Falagas ME. Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis. Intensive Care Med 2011;37:747-62. https://doi.org/10.1007/s00134-011-2174-8
- Cies JJ, Chopra A. Procalcitonin use in a pediatric intensive care unit. Pediatr Infect Dis J 2014;33:984-6. https://doi.org/10.1097/INF.0000000000000370
- Kim DS. Kawasaki disease. Yonsei Med J 2006;47:759-72. https://doi.org/10.3349/ymj.2006.47.6.759
- Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71. https://doi.org/10.1161/01.CIR.0000145143.19711.78
- Okada Y, Minakami H, Tomomasa T, Kato M, Inoue Y, Kozawa K, et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect 2004;48:199-205. https://doi.org/10.1016/j.jinf.2003.08.002
- Yoshikawa H, Nomura Y, Masuda K, Koriya C, Arata M, Hazeki D, et al. Serum procalcitonin value is useful for predicting severity of Kawasaki disease. Pediatr Infect Dis J 2012;31:523-5. https://doi.org/10.1097/INF.0b013e3182463879
- Cho HJ, Choi YE, Song ES, Cho YK, Ma JS. Procalcitonin levels in patients with complete and incomplete Kawasaki disease. Dis Markers 2013;35:505-11. https://doi.org/10.1155/2013/265051
- Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33. https://doi.org/10.1542/peds.2004-2182
- Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463-74. https://doi.org/10.1016/S0140-6736(09)61879-1
- Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, Groothuis GM, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000;28:458-61. https://doi.org/10.1097/00003246-200002000-00028
- Fernandez Lopez A, Luaces Cubells C, Garcia Garcia JJ, Fernandez Pou J; Spanish Society of Pediatric Emergencies. Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker. Pediatr Infect Dis J 2003;22:895-903. https://doi.org/10.1097/01.inf.0000091360.11784.21
- Esposito S, Tagliabue C, Picciolli I, Semino M, Sabatini C, Consolo S, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respir Med 2011;105:1939-45. https://doi.org/10.1016/j.rmed.2011.09.003
- Hatzistilianou M, Rekliti A, Athanassiadou F, Catriu D. Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res 2010;59:339-47. https://doi.org/10.1007/s00011-009-0100-0
- Galeotti C, Bayry J, Kone-Paut I, Kaveri SV. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev 2010;9:441-8. https://doi.org/10.1016/j.autrev.2009.12.004
- Kim HK, Oh J, Hong YM, Sohn S. Parameters to guide retreatment after initial intravenous immunoglobulin therapy in kawasaki disease. Korean Circ J 2011;41:379-84. https://doi.org/10.4070/kcj.2011.41.7.379
- Tremoulet AH, Jain S, Chandrasekar D, Sun X, Sato Y, Burns JC. Evolution of laboratory values in patients with Kawasaki disease. Pediatr Infect Dis J 2011;30:1022-6. https://doi.org/10.1097/INF.0b013e31822d4f56
Cited by
- Kawasaki Disease: The Role of Immune Complexes Revisited vol.10, pp.None, 2017, https://doi.org/10.3389/fimmu.2019.01156
- Biomarkers for Kawasaki Disease: Clinical Utility and the Challenges Ahead vol.7, pp.None, 2019, https://doi.org/10.3389/fped.2019.00242
- Predictive value of serum procalcitonin for both initial and repeated immunoglobulin resistance in Kawasaki disease: a prospective cohort study vol.17, pp.1, 2017, https://doi.org/10.1186/s12969-019-0379-5
- Coronary artery vasculitis: a review of current literature vol.21, pp.1, 2017, https://doi.org/10.1186/s12872-020-01813-6